Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial

Autor: van der Graaf WT, Blay, Jy, Chawla, Sp, Kim, Dw, Bui Nguyen, B, Casali, Pg, Schöffski, P, Aglietta, Massimo, Staddon, Ap, Beppu, Y, Le Cesne, A, Gelderblom, H, Judson, Ir, Araki, N, Ouali, M, Marreaud, S, Hodge, R, Dewji, Mr, Coens, C, Demetri, Gd, Fletcher, Cd, Dei Tos AP, Hohenberger, P, EORTC Soft Tissue, Bone Sarcoma Group, PALETTE study group

Publikováno v: The Lancet (London), 379, 1879-86
The Lancet (London), 379, 9829, pp. 1879-86
Lancet, 379(9829), 1879-1886

Item does not contain fulltext BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e504ee0ea9c1bc33830fe09e5cdb03b4
https://www.ncbi.nlm.nih.gov/pubmed/22595799

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

Autor: Benson C; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: charlotte.benson@rmh.nhs.uk., Ray-Coquard I; Centre Leon Berard, University Claude Bernard, Lyon, France., Sleijfer S; Erasmus Medical Centre, Rotterdam, The Netherlands., Litière S; EORTC Headquarters, Brussels, Belgium., Blay JY; Centre Leon Berard, University Claude Bernard, Lyon, France., Le Cesne A; Institut Gustave Roussy, Villejuif, France., Papai Z; Military Hospital-State Health Centre, Budapest, Hungary., Judson I; Royal Marsden NHS Foundation Trust, London, UK., Schöffski P; University Hospitals Leuven-KU Leuven, Leuven, Belgium., Chawla S; Sarcoma Oncology Centre, Santa Monica, USA., Gil T; Institut Jules Bordet, Brussels, Belgium., Piperno-Neumann S; Institut Curie, Paris, France., Marréaud S; EORTC Headquarters, Brussels, Belgium., Dewji MR; Novartis Pharma AG, Basel, Switzerland., van der Graaf WTA; Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2016 Jul; Vol. 142 (1), pp. 89-94. Date of Electronic Publication: 2016 Apr 29.